Showing 1189 results
-
Press Release /Telemedicine pilot in rural Ghana demonstrated positive impact and improved primary health services as reported by nurses, midwives and patients Retrospective contact tracing of former leprosy…
-
Press Release /Farydak (panobinostat) combination is approved in the EU for patients with multiple myeloma who received >=2 prior regimens including bortezomib and IMiD[1] In clinical trials, Farydak…
-
Press Release /Launch follows March 6, 2015 FDA approval Sandoz One SourceTM offers patient support services The digital press release with multimedia content can be accessed here: Holzkirchen,…
-
Press Release /Revolade is the first approved therapy in the EU for patients with severe aplastic anemia (SAA) who have not responded to other treatments Patients living with SAA, a rare blood disorder,…
-
Press Release /The companies plan to co-develop and co-commercialize a BACE inhibitor program in Alzheimer's Disease (AD); Novartis' oral therapy CNP520 will be the lead molecule Novartis and Amgen also plan…
-
Press Release /Die Vereinbarung für die kommenden fünf Jahre umfasst Spenden von Behandlungseinheiten im Wert von mehr als USD 40 Millionen, mit denen rund 1,3 Millionen Patienten geholfen werden…
-
Press Release /Ce nouvel engagement sur cinq ans comprend un don de médicaments d'une valeur estimée à plus d'USD 40 millions qui devrait permettre de traiter environ 1,3 million de patients Le nouveau…
-
Press Release /Approval based on two Phase III studies demonstrating statistically significant overall survival benefit with combination therapy vs BRAF inhibitor monotherapy Targeted combination offers…
-
Press Release /New five-year commitment includes donation of treatments worth more than USD 40 million and is expected to reach an estimated 1.3 million patients Novartis Foundation's new leprosy contact…
-
Press Release /Das International Biotechnology Leadership Camp (BioCamp) fördert das Interesse von Studierenden für wissenschaftlichen Fortschritt und unternehmerische Chancen Anlässlich des interaktiven Programms…